Cargando…

Clinical and imaging features of myeloid sarcoma: a German multicenter study

BACKGROUND: Myeloid sarcoma (MS), also known as chloroma, is an extramedullary manifestation of malignant primitive myeloid cells. Previously, only small studies investigated clinical and imaging features of MS. The purpose of this study was to elucidate clinical and imaging features of MS based upo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Hans-Jonas, Pönisch, Wolfram, Schmidt, Stefan Andreas, Wienbeck, Susanne, Braulke, Friederike, Schramm, Dominik, Surov, Alexey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882227/
https://www.ncbi.nlm.nih.gov/pubmed/31775680
http://dx.doi.org/10.1186/s12885-019-6357-y
_version_ 1783474110607654912
author Meyer, Hans-Jonas
Pönisch, Wolfram
Schmidt, Stefan Andreas
Wienbeck, Susanne
Braulke, Friederike
Schramm, Dominik
Surov, Alexey
author_facet Meyer, Hans-Jonas
Pönisch, Wolfram
Schmidt, Stefan Andreas
Wienbeck, Susanne
Braulke, Friederike
Schramm, Dominik
Surov, Alexey
author_sort Meyer, Hans-Jonas
collection PubMed
description BACKGROUND: Myeloid sarcoma (MS), also known as chloroma, is an extramedullary manifestation of malignant primitive myeloid cells. Previously, only small studies investigated clinical and imaging features of MS. The purpose of this study was to elucidate clinical and imaging features of MS based upon a multicenter patient sample. METHODS: Patient records of radiological databases of 4 German university hospitals were retrospectively screened for MS in the time period 01/2001 and 06/2019. Overall, 151 cases/76 females (50.3%) with a mean age of 55.5 ± 15.1 years and 183 histopathological confirmation or clinically suspicious lesions of MS were included into this study. The underlying hematological disease, localizations, and clinical symptoms as well as imaging features on CT and MRI were investigated. RESULTS: In 15 patients (9.9% of all 151 cases) the manifestation of MS preceded the systemic hematological disease. In 43 cases (28.4%), first presentation of MS occurred simultaneously with the initial diagnosis of leukemia, and 92 (60.9%) patients presented MS after the initial diagnosis. In 37 patients (24.5%), the diagnosis was made incidentally by imaging. Clinically, cutaneous lesions were detected in 35 of 151 cases (23.2%). Other leading symptoms were pain (n = 28/151, 18.5%), neurological deficit (n = 27/151, 17.9%), swelling (n = 14/151, 9.3%) and dysfunction of the affected organ (n = 10/151, 6.0%). Most commonly, skin was affected (n = 30/151, 16.6%), followed by bone (n = 29/151, 16.0%) and lymphatic tissue (n = 21/151, 11.4%). Other localizations were rare. On CT, most lesions were homogenous. On T2-weighted imaging, most of the lesions were hyperintense. On T1-weighted images, MS was hypointense in n = 22/54 (40.7%) and isointense in n = 30/54 (55.6%). A diffusion restriction was identified in most cases with a mean ADC value of 0.76 ± 0.19 × 10(− 3) mm(2)/s. CONCLUSIONS: The present study shows clinical and imaging features of MS based upon a large patient sample in a multicenter design. MS occurs in most cases meta-chronous to the hematological disease and most commonly affects the cutis. One fourth of cases were identified incidentally on imaging, which needs awareness of the radiologists for possible diagnosis of MS.
format Online
Article
Text
id pubmed-6882227
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68822272019-12-03 Clinical and imaging features of myeloid sarcoma: a German multicenter study Meyer, Hans-Jonas Pönisch, Wolfram Schmidt, Stefan Andreas Wienbeck, Susanne Braulke, Friederike Schramm, Dominik Surov, Alexey BMC Cancer Research Article BACKGROUND: Myeloid sarcoma (MS), also known as chloroma, is an extramedullary manifestation of malignant primitive myeloid cells. Previously, only small studies investigated clinical and imaging features of MS. The purpose of this study was to elucidate clinical and imaging features of MS based upon a multicenter patient sample. METHODS: Patient records of radiological databases of 4 German university hospitals were retrospectively screened for MS in the time period 01/2001 and 06/2019. Overall, 151 cases/76 females (50.3%) with a mean age of 55.5 ± 15.1 years and 183 histopathological confirmation or clinically suspicious lesions of MS were included into this study. The underlying hematological disease, localizations, and clinical symptoms as well as imaging features on CT and MRI were investigated. RESULTS: In 15 patients (9.9% of all 151 cases) the manifestation of MS preceded the systemic hematological disease. In 43 cases (28.4%), first presentation of MS occurred simultaneously with the initial diagnosis of leukemia, and 92 (60.9%) patients presented MS after the initial diagnosis. In 37 patients (24.5%), the diagnosis was made incidentally by imaging. Clinically, cutaneous lesions were detected in 35 of 151 cases (23.2%). Other leading symptoms were pain (n = 28/151, 18.5%), neurological deficit (n = 27/151, 17.9%), swelling (n = 14/151, 9.3%) and dysfunction of the affected organ (n = 10/151, 6.0%). Most commonly, skin was affected (n = 30/151, 16.6%), followed by bone (n = 29/151, 16.0%) and lymphatic tissue (n = 21/151, 11.4%). Other localizations were rare. On CT, most lesions were homogenous. On T2-weighted imaging, most of the lesions were hyperintense. On T1-weighted images, MS was hypointense in n = 22/54 (40.7%) and isointense in n = 30/54 (55.6%). A diffusion restriction was identified in most cases with a mean ADC value of 0.76 ± 0.19 × 10(− 3) mm(2)/s. CONCLUSIONS: The present study shows clinical and imaging features of MS based upon a large patient sample in a multicenter design. MS occurs in most cases meta-chronous to the hematological disease and most commonly affects the cutis. One fourth of cases were identified incidentally on imaging, which needs awareness of the radiologists for possible diagnosis of MS. BioMed Central 2019-11-27 /pmc/articles/PMC6882227/ /pubmed/31775680 http://dx.doi.org/10.1186/s12885-019-6357-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Meyer, Hans-Jonas
Pönisch, Wolfram
Schmidt, Stefan Andreas
Wienbeck, Susanne
Braulke, Friederike
Schramm, Dominik
Surov, Alexey
Clinical and imaging features of myeloid sarcoma: a German multicenter study
title Clinical and imaging features of myeloid sarcoma: a German multicenter study
title_full Clinical and imaging features of myeloid sarcoma: a German multicenter study
title_fullStr Clinical and imaging features of myeloid sarcoma: a German multicenter study
title_full_unstemmed Clinical and imaging features of myeloid sarcoma: a German multicenter study
title_short Clinical and imaging features of myeloid sarcoma: a German multicenter study
title_sort clinical and imaging features of myeloid sarcoma: a german multicenter study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882227/
https://www.ncbi.nlm.nih.gov/pubmed/31775680
http://dx.doi.org/10.1186/s12885-019-6357-y
work_keys_str_mv AT meyerhansjonas clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT ponischwolfram clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT schmidtstefanandreas clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT wienbecksusanne clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT braulkefriederike clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT schrammdominik clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy
AT surovalexey clinicalandimagingfeaturesofmyeloidsarcomaagermanmulticenterstudy